Listed

LENZ Therapeutics, Inc.

LENZNasdaqCIK 1815776HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$5.5m, Q2 FY2026
Operating income−$34.2m, Q2 FY2026
Net income−$31.9m, Q2 FY2026
LENZ Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$mnot reportednot reportednot reported0.0Revenue, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-07-30, accession 0001815776-25-000056.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-24, accession 0001815776-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure5.0Revenue, Q2 FY2025, three months to 2025-06-30$5.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure12.5Revenue, Q3 FY2025, three months to 2025-09-30$12.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure1.6Revenue, Q4 FY2025, three months to 2025-12-31$1.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-24, accession 0001815776-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure1.9Revenue, Q1 FY2026, three months to 2026-03-31$1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure5.5Revenue, Q2 FY2026, three months to 2026-06-30$5.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure
Cost of revenue$mnot reportednot reportednot reportednot reportednot reportednot reported0.0Cost of revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure0.0Cost of revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figurenot reportednot reported1.1Cost of revenue, Q1 FY2026, three months to 2026-03-31$1.1m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure0.3Cost of revenue, Q2 FY2026, three months to 2026-06-30$280.0k. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure
Research and development$m17.0Research and development, Q3 FY2023, three months to 2023-09-30$17.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-06, accession 0001815776-24-000071.Report this figure19.5Research and development, Q4 FY2023, three months to 2023-12-31$19.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-19, accession 0001815776-25-000019. Derived: 12-month figure less the 9-month figure.Report this figure10.5Research and development, Q1 FY2024, three months to 2024-03-31$10.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-07, accession 0001815776-25-000032.Report this figure6.9Research and development, Q2 FY2024, three months to 2024-06-30$6.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-07-30, accession 0001815776-25-000056.Report this figure6.5Research and development, Q3 FY2024, three months to 2024-09-30$6.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure5.9Research and development, Q4 FY2024, three months to 2024-12-31$5.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-24, accession 0001815776-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure5.8Research and development, Q1 FY2025, three months to 2025-03-31$5.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure9.1Research and development, Q2 FY2025, three months to 2025-06-30$9.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure3.8Research and development, Q3 FY2025, three months to 2025-09-30$3.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure0.0Research and development, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-24, accession 0001815776-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure0.0Research and development, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure0.0Research and development, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure
Selling, general and administrative$m2.9Selling, general and administrative, Q3 FY2023, three months to 2023-09-30$2.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2024-11-06, accession 0001815776-24-000071.Report this figure5.5Selling, general and administrative, Q4 FY2023, three months to 2023-12-31$5.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2025-03-19, accession 0001815776-25-000019. Derived: 12-month figure less the 9-month figure.Report this figure5.6Selling, general and administrative, Q1 FY2024, three months to 2024-03-31$5.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-05-07, accession 0001815776-25-000032.Report this figure7.4Selling, general and administrative, Q2 FY2024, three months to 2024-06-30$7.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-07-30, accession 0001815776-25-000056.Report this figure6.5Selling, general and administrative, Q3 FY2024, three months to 2024-09-30$6.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure9.4Selling, general and administrative, Q4 FY2024, three months to 2024-12-31$9.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-03-24, accession 0001815776-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure11.1Selling, general and administrative, Q1 FY2025, three months to 2025-03-31$11.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure12.8Selling, general and administrative, Q2 FY2025, three months to 2025-06-30$12.8m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure27.6Selling, general and administrative, Q3 FY2025, three months to 2025-09-30$27.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure39.6Selling, general and administrative, Q4 FY2025, three months to 2025-12-31$39.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-03-24, accession 0001815776-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure45.0Selling, general and administrative, Q1 FY2026, three months to 2026-03-31$45.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure39.4Selling, general and administrative, Q2 FY2026, three months to 2026-06-30$39.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure
Operating income$m(19.9)Operating income, Q3 FY2023, three months to 2023-09-30−$19.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-06, accession 0001815776-24-000071.Report this figure(25.0)Operating income, Q4 FY2023, three months to 2023-12-31−$25.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-19, accession 0001815776-25-000019. Derived: 12-month figure less the 9-month figure.Report this figure(16.1)Operating income, Q1 FY2024, three months to 2024-03-31−$16.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-07, accession 0001815776-25-000032.Report this figure(14.4)Operating income, Q2 FY2024, three months to 2024-06-30−$14.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-07-30, accession 0001815776-25-000056.Report this figure(12.9)Operating income, Q3 FY2024, three months to 2024-09-30−$12.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure(15.2)Operating income, Q4 FY2024, three months to 2024-12-31−$15.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-24, accession 0001815776-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(16.9)Operating income, Q1 FY2025, three months to 2025-03-31−$16.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure(16.9)Operating income, Q2 FY2025, three months to 2025-06-30−$16.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure(18.9)Operating income, Q3 FY2025, three months to 2025-09-30−$18.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure(38.5)Operating income, Q4 FY2025, three months to 2025-12-31−$38.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-24, accession 0001815776-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(44.1)Operating income, Q1 FY2026, three months to 2026-03-31−$44.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure(34.2)Operating income, Q2 FY2026, three months to 2026-06-30−$34.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure
Income tax$mnot reportednot reportednot reported0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-07-30, accession 0001815776-25-000056.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$1.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-24, accession 0001815776-26-000011. Derived: 12-month figure less the 9-month figure.Report this figurenot reported0.5Income tax, Q2 FY2025, three months to 2025-06-30$500.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-12-31$2.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-24, accession 0001815776-26-000011. Derived: 12-month figure less the 9-month figure.Report this figurenot reported0.0Income tax, Q2 FY2026, three months to 2026-06-30$3.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure
Net income$m(18.9)Net income, Q3 FY2023, three months to 2023-09-30−$18.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-06, accession 0001815776-24-000071.Report this figure(23.7)Net income, Q4 FY2023, three months to 2023-12-31−$23.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-19, accession 0001815776-25-000019. Derived: 12-month figure less the 9-month figure.Report this figure(16.6)Net income, Q1 FY2024, three months to 2024-03-31−$16.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure(10.3)Net income, Q2 FY2024, three months to 2024-06-30−$10.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure(10.2)Net income, Q3 FY2024, three months to 2024-09-30−$10.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure(12.7)Net income, Q4 FY2024, three months to 2024-12-31−$12.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-24, accession 0001815776-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(14.6)Net income, Q1 FY2025, three months to 2025-03-31−$14.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure(14.9)Net income, Q2 FY2025, three months to 2025-06-30−$14.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure(16.7)Net income, Q3 FY2025, three months to 2025-09-30−$16.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure(35.9)Net income, Q4 FY2025, three months to 2025-12-31−$35.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-24, accession 0001815776-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(41.5)Net income, Q1 FY2026, three months to 2026-03-31−$41.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure(31.9)Net income, Q2 FY2026, three months to 2026-06-30−$31.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure
Diluted EPS$ per share(9.62)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$9.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-06, accession 0001815776-24-000071.Report this figurenot reported(3.53)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$3.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-07, accession 0001815776-25-000032.Report this figure(0.40)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-07-30, accession 0001815776-25-000056.Report this figure(0.38)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.38 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figurenot reported(0.53)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure(0.53)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure(0.59)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.59 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figurenot reported(1.32)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$1.32 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure(1.02)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure
Basic EPS$ per share(9.62)Basic EPS, Q3 FY2023, three months to 2023-09-30−$9.62 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-06, accession 0001815776-24-000071.Report this figurenot reported(3.53)Basic EPS, Q1 FY2024, three months to 2024-03-31−$3.53 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-07, accession 0001815776-25-000032.Report this figure(0.40)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.40 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-07-30, accession 0001815776-25-000056.Report this figure(0.38)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.38 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figurenot reported(0.53)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.53 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure(0.53)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.53 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure(0.59)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.59 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figurenot reported(1.32)Basic EPS, Q1 FY2026, three months to 2026-03-31−$1.32 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure(1.02)Basic EPS, Q2 FY2026, three months to 2026-06-30−$1.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure

Balance sheet

Cash and equivalents$24.2m, Q2 FY2026
Shareholders' equity$219.3m, Q2 FY2026
LENZ Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m183Cash and equivalents, Q3 FY2023, at 2023-09-30$183.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-13, accession 0000950170-23-062942.Report this figure35.1Cash and equivalents, FY2023, at 2023-12-31$35.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-19, accession 0001815776-25-000019.Report this figure200Cash and equivalents, Q1 FY2024, at 2024-03-31$200.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-08, accession 0001815776-24-000042.Report this figure84.0Cash and equivalents, Q2 FY2024, at 2024-06-30$84.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-14, accession 0001815776-24-000060.Report this figure41.0Cash and equivalents, Q3 FY2024, at 2024-09-30$41.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-06, accession 0001815776-24-000071.Report this figure20.2Cash and equivalents, FY2024, at 2024-12-31$20.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-24, accession 0001815776-26-000011.Report this figure23.0Cash and equivalents, Q1 FY2025, at 2025-03-31$23.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-07, accession 0001815776-25-000032.Report this figure37.6Cash and equivalents, Q2 FY2025, at 2025-06-30$37.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-07-30, accession 0001815776-25-000056.Report this figure25.4Cash and equivalents, Q3 FY2025, at 2025-09-30$25.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure25.2Cash and equivalents, FY2025, at 2025-12-31$25.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure24.8Cash and equivalents, Q1 FY2026, at 2026-03-31$24.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure24.2Cash and equivalents, Q2 FY2026, at 2026-06-30$24.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure
Current assets$m239Current assets, Q3 FY2023, at 2023-09-30$238.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-13, accession 0000950170-23-062942.Report this figure67.2Current assets, FY2023, at 2023-12-31$67.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-19, accession 0001815776-25-000019.Report this figure217Current assets, Q1 FY2024, at 2024-03-31$216.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-08, accession 0001815776-24-000042.Report this figure199Current assets, Q2 FY2024, at 2024-06-30$199.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-14, accession 0001815776-24-000060.Report this figure221Current assets, Q3 FY2024, at 2024-09-30$220.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-06, accession 0001815776-24-000071.Report this figure212Current assets, FY2024, at 2024-12-31$211.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-24, accession 0001815776-26-000011.Report this figure198Current assets, Q1 FY2025, at 2025-03-31$197.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-07, accession 0001815776-25-000032.Report this figure214Current assets, Q2 FY2025, at 2025-06-30$213.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-07-30, accession 0001815776-25-000056.Report this figure207Current assets, Q3 FY2025, at 2025-09-30$207.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure301Current assets, FY2025, at 2025-12-31$301.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure268Current assets, Q1 FY2026, at 2026-03-31$268.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure233Current assets, Q2 FY2026, at 2026-06-30$233.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure
Total assets$m266Total assets, Q3 FY2023, at 2023-09-30$266.2m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-13, accession 0000950170-23-062942.Report this figure70.4Total assets, FY2023, at 2023-12-31$70.4m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-19, accession 0001815776-25-000019.Report this figure217Total assets, Q1 FY2024, at 2024-03-31$217.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-08, accession 0001815776-24-000042.Report this figure203Total assets, Q2 FY2024, at 2024-06-30$202.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-14, accession 0001815776-24-000060.Report this figure224Total assets, Q3 FY2024, at 2024-09-30$224.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-06, accession 0001815776-24-000071.Report this figure215Total assets, FY2024, at 2024-12-31$215.3m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-24, accession 0001815776-26-000011.Report this figure201Total assets, Q1 FY2025, at 2025-03-31$201.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-07, accession 0001815776-25-000032.Report this figure217Total assets, Q2 FY2025, at 2025-06-30$217.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-07-30, accession 0001815776-25-000056.Report this figure211Total assets, Q3 FY2025, at 2025-09-30$210.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure306Total assets, FY2025, at 2025-12-31$305.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure273Total assets, Q1 FY2026, at 2026-03-31$272.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure237Total assets, Q2 FY2026, at 2026-06-30$236.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure
Current liabilities$m12.5Current liabilities, Q3 FY2023, at 2023-09-30$12.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-13, accession 0000950170-23-062942.Report this figure18.5Current liabilities, FY2023, at 2023-12-31$18.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-19, accession 0001815776-25-000019.Report this figure18.9Current liabilities, Q1 FY2024, at 2024-03-31$18.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-08, accession 0001815776-24-000042.Report this figure8.6Current liabilities, Q2 FY2024, at 2024-06-30$8.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-14, accession 0001815776-24-000060.Report this figure7.7Current liabilities, Q3 FY2024, at 2024-09-30$7.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-06, accession 0001815776-24-000071.Report this figure10.4Current liabilities, FY2024, at 2024-12-31$10.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-24, accession 0001815776-26-000011.Report this figure8.6Current liabilities, Q1 FY2025, at 2025-03-31$8.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-07, accession 0001815776-25-000032.Report this figure10.4Current liabilities, Q2 FY2025, at 2025-06-30$10.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-07-30, accession 0001815776-25-000056.Report this figure16.3Current liabilities, Q3 FY2025, at 2025-09-30$16.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure21.2Current liabilities, FY2025, at 2025-12-31$21.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure25.8Current liabilities, Q1 FY2026, at 2026-03-31$25.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure17.2Current liabilities, Q2 FY2026, at 2026-06-30$17.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure
Total liabilities$m62.2Total liabilities, Q3 FY2023, at 2023-09-30$62.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-13, accession 0000950170-23-062942.Report this figure19.7Total liabilities, FY2023, at 2023-12-31$19.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-19, accession 0001815776-25-000019.Report this figure19.2Total liabilities, Q1 FY2024, at 2024-03-31$19.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-08, accession 0001815776-24-000042.Report this figure9.7Total liabilities, Q2 FY2024, at 2024-06-30$9.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-14, accession 0001815776-24-000060.Report this figure8.7Total liabilities, Q3 FY2024, at 2024-09-30$8.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-06, accession 0001815776-24-000071.Report this figure11.2Total liabilities, FY2024, at 2024-12-31$11.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-24, accession 0001815776-26-000011.Report this figure9.2Total liabilities, Q1 FY2025, at 2025-03-31$9.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-07, accession 0001815776-25-000032.Report this figure11.0Total liabilities, Q2 FY2025, at 2025-06-30$11.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-07-30, accession 0001815776-25-000056.Report this figure16.8Total liabilities, Q3 FY2025, at 2025-09-30$16.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure21.5Total liabilities, FY2025, at 2025-12-31$21.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure26.0Total liabilities, Q1 FY2026, at 2026-03-31$26.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure17.3Total liabilities, Q2 FY2026, at 2026-06-30$17.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure
Shareholders' equity$m(69.6)Shareholders' equity, Q3 FY2023, at 2023-09-30−$69.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-06, accession 0001815776-24-000071.Report this figure(92.7)Shareholders' equity, FY2023, at 2023-12-31−$92.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-24, accession 0001815776-26-000011.Report this figure198Shareholders' equity, Q1 FY2024, at 2024-03-31$198.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure193Shareholders' equity, Q2 FY2024, at 2024-06-30$192.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure215Shareholders' equity, Q3 FY2024, at 2024-09-30$215.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure204Shareholders' equity, FY2024, at 2024-12-31$204.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure192Shareholders' equity, Q1 FY2025, at 2025-03-31$192.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure206Shareholders' equity, Q2 FY2025, at 2025-06-30$206.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure194Shareholders' equity, Q3 FY2025, at 2025-09-30$193.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure284Shareholders' equity, FY2025, at 2025-12-31$284.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure246Shareholders' equity, Q1 FY2026, at 2026-03-31$246.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure219Shareholders' equity, Q2 FY2026, at 2026-06-30$219.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure

Cash flow

Operating cash flow−$38.7m, Q2 FY2026
Capital expenditure$16.0k, Q2 FY2026
LENZ Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(13.1)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$13.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-06, accession 0001815776-24-000071. Derived: 9-month figure less the 6-month figure.Report this figure(21.0)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$21.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-19, accession 0001815776-25-000019. Derived: 12-month figure less the 9-month figure.Report this figure(23.9)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$23.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-07, accession 0001815776-25-000032.Report this figure(15.8)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$15.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-07-30, accession 0001815776-25-000056. Derived: 6-month figure less the 3-month figure.Report this figure(10.6)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$10.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001815776-25-000071. Derived: 9-month figure less the 6-month figure.Report this figure(9.1)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$9.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-24, accession 0001815776-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(16.0)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$16.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure(11.5)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$11.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001815776-26-000052. Derived: 6-month figure less the 3-month figure.Report this figure(8.6)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$8.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001815776-25-000071. Derived: 9-month figure less the 6-month figure.Report this figure(33.0)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$33.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-24, accession 0001815776-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure(33.6)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$33.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure(38.7)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$38.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001815776-26-000052. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-06, accession 0001815776-24-000071. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-19, accession 0001815776-25-000019. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-07, accession 0001815776-25-000032.Report this figure0.1Capital expenditure, Q2 FY2024, three months to 2024-06-30$133.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-07-30, accession 0001815776-25-000056. Derived: 6-month figure less the 3-month figure.Report this figure0.2Capital expenditure, Q3 FY2024, three months to 2024-09-30$186.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001815776-25-000071. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2024, three months to 2024-12-31$149.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-24, accession 0001815776-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2025, three months to 2025-03-31$110.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure0.2Capital expenditure, Q2 FY2025, three months to 2025-06-30$240.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001815776-26-000052. Derived: 6-month figure less the 3-month figure.Report this figure0.4Capital expenditure, Q3 FY2025, three months to 2025-09-30$439.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001815776-25-000071. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$38.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-24, accession 0001815776-26-000011. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$18.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$16.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001815776-26-000052. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)31.37m, Q2 FY2026
LENZ Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares55.2Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3055,206,139 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-13, accession 0000950170-23-062942.Report this figure2.0Diluted shares (weighted), Q1 FY2023, three months to 2023-03-311,950,653 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-08, accession 0001815776-24-000042.Report this figure2.0Diluted shares (weighted), Q2 FY2023, three months to 2023-06-301,956,244 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-14, accession 0001815776-24-000060.Report this figure2.0Diluted shares (weighted), Q3 FY2023, three months to 2023-09-301,961,822 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-06, accession 0001815776-24-000071.Report this figure4.7Diluted shares (weighted), Q1 FY2024, three months to 2024-03-314,717,613 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-07, accession 0001815776-25-000032.Report this figure25.6Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3025,608,594 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-07-30, accession 0001815776-25-000056.Report this figure27.2Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3027,172,330 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure27.5Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3127,526,099 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure28.1Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3028,079,071 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure28.5Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3028,540,519 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001815776-25-000071.Report this figure31.4Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3131,352,702 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001815776-26-000037.Report this figure31.4Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3031,374,311 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure

Shares outstanding: 31.42mShares outstanding, period not labelled, at 2026-08-0531,420,343 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-11, accession 0001815776-26-000052.Report this figure at Aug 5, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.